-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: iHuPBMC-MHC/KO
Author:
InnoModels Biotechnology
Release time:
2024-01-19
Once again demonstrating a strong commitment to innovation in the biomedical field, InnoModels Biotechnology introduces the iHuPBMC-MHC/KO, an innovative product for immunological research. iHuPBMC-MHC/KO is a forward-thinking product that provides scientists with groundbreaking tools to advance immunological research and expand our understanding of the immune system.
Technical Breakthrough of iHuPBMC-MHC/KO
iHuPBMC-MHC/KO is a model based on Human Peripheral Blood Mononuclear Cells (iHuPBMC) with a special focus on Major Histocompatibility Complex (MHC) Knockout (KO). The following are its major technological breakthroughs:
Main Features and Advantages
1. MHC knockout technology:
iHuPBMC-MHC/KO uses advanced gene editing technology to successfully realize MHC gene knockout. This allows researchers to simulate the effects of MHC deletion on the immune system under specific conditions, providing a completely new perspective for immunological research.
2. Research on the mechanism of immune tolerance and rejection:
Modeling provides an ideal platform for studying immune tolerance and rejection mechanisms. Through MHC knockdown, how the immune system responds to the missing MHC can be explored in depth, providing new ideas for organ transplantation and autoimmune disease research.
3. Personalized immunotherapy development:
iHuPBMC-MHC/KO is expected to support the development of personalized immunotherapy. By mimicking different MHC genotypes, researchers can better understand the immune system response to individualized therapies.

Scientific applications and future perspectives
1. Immunomodulatory disease therapy:
iHuPBMC-MHC/KO provides a new research tool for the study of immune-modulated disease therapy, which is expected to provide a scientific basis for the design of therapeutic strategies for inflammatory diseases and autoimmune diseases.
2. organ transplantation research:
The model provides unprecedented opportunities for the study of immune rejection in organ transplantation, which is expected to promote innovative development in the field of organ transplantation.
3. Future Innovation Direction:
InnoModels Biotechnology will continue to invest in research and development to explore new areas of immunology and clinical applications of iHuPBMC-MHC/KO, and to promote greater breakthroughs in immunology research.
Conclusion
The launch of iHuPBMC-MHC/KO marks an outstanding innovation in the field of immunology by InnoModels Biotechnology. The unique nature of this product provides scientists with a powerful tool that is expected to drive research progress in the field of immunology and offer more possibilities for future immunotherapy and disease treatment.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd